Tablets sold as diazepam
Novel benzodiazepines were identified in place of the expected medicine. Pharmaceutical-style appearance and packaging did not authenticate the tested products.
Early warning and preparedness
Emerging threats
TD analytical priorities combining national mortality, submitted-sample testing, rapid surveillance, treatment, wastewater and evidence reviews. These are not official national alert levels.
Editorial review: 4 November 2026Signals assessed12Substances and market presentations
Critical2Nitazenes and Orphines
High priority6Sedatives, ketamine and gabapentinoids
Horizon monitoring4Stimulants, GBL/GHB and Tusi
How to read the assessments
The matrix includes orphines, ketamine, gabapentinoids, methamphetamine, synthetic cathinones and GBL/GHB alongside other signals. These are TD priorities, separate from evidence confidence and direction of change. Qualitative evidence confidence rates the specific dated finding for each signal; it is not a probability or risk score. Inclusion does not establish national prevalence.
Unexpected contents in submitted products
WEDINOS UK submissions, April 2025–March 2026
Report published 25 August 2026 · evidence checked 12 October 2026
Products sold as oxycodone
Some submitted samples contained nitazenes. Purchase intent among nitazene-positive samples is a different denominator from all submitted oxycodone or all oxycodone sold.
Products sold as THC, CBD or cannabis vapes
Synthetic cannabinoid receptor agonists were identified in submitted products.
Selected samples, not market prevalence. These are selected analytical findings, not estimates of how common substitution is across the UK market. The existing Orphines and Tusi assessments above cover other documented unexpected mixtures.